Pernix Therapeutics Holdings (PTX) has risen sharply, recording gains of 5.24% in the past 4 weeks. However, the stock has corrected -5.13% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.84% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has recorded a 20-day Moving Average of 4.48% and the 50-Day Moving Average is 4.1%.
Pernix Therapeutics Holdings (NASDAQ:PTX): The stock opened at $0.57 on Friday but the bulls could not build on the opening and the stock topped out at $0.60 for the day. The stock traded down to $0.51 during the day, due to lack of any buying support eventually closed down at $0.52 with a loss of -10.02% for the day. The stock had closed at $0.58 on the previous day. The total traded volume was 4,847,786 shares.
The company Insiders own 5.62% of Pernix Therapeutics Holdings shares according to the proxy statements. Institutional Investors own 64.95% of Pernix Therapeutics Holdings shares. In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc., Siegel Barry J had purchased shares worth of $22,450 in a transaction dated on August 19, 2015. A total of 5,000 shares were purchased at a price of $4.49 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).